Elicio Therapeutics, Inc. cotiza a 1.75 USD y tiene una capitalización bursátil de $47M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog dri…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.65 | $-0.49 | $-0.60 | $-0.66 |
| Estimado | $-0.46 | $-0.44 | $-0.48 | $-0.68 |
| Sorpresa | -41.3% | -11.4% | -25.0% | +2.9% |
| Métrica | ELTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -2418.8% | -40.4% | -2378.4% |
| ROA | -153.0% | -32.0% | -121.0% |
| Current Ratio | 2.38 | 2.84 | -0.46 |
| Debt / Equity | 6.11 | 0.28 | +5.83 |